Market Cap 6.24B
Revenue (ttm) 0.00
Net Income (ttm) -463.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 545,300
Avg Vol 1,472,782
Day's Range N/A - N/A
Shares Out 130.91M
Stochastic %K 84%
Beta 1.28
Analysts Strong Sell
Price Target $99.89

Company Profile

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conju...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 837 0111
Website: vaxcyte.com
Address:
825 Industrial Road, Suite 300, San Carlos, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:57 PM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $47.65, showing a stable position above the 30-day moving average (MA30) of $46.66 and the 50-day moving average (MA50) of $45.21. The RSI at 56.89 indicates bullish momentum without being overbought, suggesting potential for upward movement. Directional Bias: The recent price action is positive, as the stock is closer to the 60-day high of $50.27 than the low of $36.15. This indicates a bullish sentiment in the market. Trade Plan: - Suggested Entry: $47.70 (slightly above last close) - Stop Loss: $45.50 (below MA50 for safety) - Take Profit Targets: 1. $49.00 (4% gain) 2. $50.00 (5.5% gain) 3. $55.75 (17% gain) This plan leverages the current bullish trend while maintaining a reasonable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
TheNewNormalN
TheNewNormalN Dec. 25 at 11:36 AM
$PCVX A transition phase is underway where operating consistency matters more than rapid expansion. Operating leverage needs to emerge without sacrificing balance‑sheet resilience. Sharper prioritization may be required to avoid execution dilution. The market will respond to evidence, not speculation.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:54 PM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $43.71, showing a significant decline from its 60-day high of $50.27. The RSI at 31.81 indicates that the stock is oversold, suggesting a potential reversal. The price is also below both the 30-day MA (46.06) and the 50-day MA (44.86), indicating bearish momentum, but the oversold RSI presents a buying opportunity. Directional Bias: Given the oversold condition and proximity to the 60-day low of $31.89, we anticipate a bullish reversal. Trade Plan: - Suggested Entry: $43.71 - Stop Loss: $41.57 (approximately 5% below entry) - Take Profit Targets: - TP1: $46.00 (5.25% gain) - TP2: $48.00 (9.76% gain) - TP3: $51.00 (16.54% gain) This plan offers a potential ROI of over 17% on TP3 while maintaining a manageable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:39 AM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $43.67, significantly below the 30-day moving average (MA30) of $45.89 and the 50-day moving average (MA50) of $44.77, indicating bearish momentum. The RSI at 28.93 suggests the stock is oversold, presenting a potential reversal opportunity. Directional Bias: Given the oversold RSI and proximity to the 60-day low of $31.89, there is a bullish bias for a potential recovery towards the 60-day high of $50.27. Trade Plan: - Suggested Entry: $43.67 (last close) - Stop Loss: $41.57 (below recent support, approximately 5% risk) - Take Profit Targets: 1. $46.00 (10% gain) 2. $48.00 (10% gain) 3. $51.00 (17% gain) This plan allows for a risk-reward ratio that aligns with a potential recovery, leveraging the oversold condition and recent price action. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:12 AM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $44.5, showing potential for upward movement. The RSI at 40.48 indicates that the stock is approaching oversold territory, suggesting a possible rebound. The proximity to the 60D Low of $30.89 provides a favorable risk-reward setup. Directional Bias: The stock is below both the MA30 (45.89) and MA50 (44.69), indicating bearish pressure. However, the RSI suggests a potential reversal, and the recent price action is near the lower end of its 60-day range. Trade Plan: - Suggested Entry: $44.5 - Stop Loss: $42.5 (1.5 ATR below entry) - Take Profit Targets: - TP1: $46.5 (4.5% gain) - TP2: $48.0 (7.5% gain) - TP3: $52.0 (17% gain) This trade plan offers a clear path for profit while managing risk effectively. Monitor the stock closely for any changes in momentum. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
infiniteM
infiniteM Dec. 13 at 8:21 AM
$PCVX tokd you....
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:06 AM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $44.57, showing a neutral RSI of 41.0, indicating potential for upward movement as it is not overbought. The price is below the 30-day moving average (MA30) of $45.9 and slightly above the 50-day moving average (MA50) of $44.6, suggesting a possible reversal or consolidation phase. Directional Bias: Given the RSI and proximity to both MAs, there is a bullish bias. The recent 60-day high of $50.27 presents a target for upward momentum, while the 60-day low of $30.89 provides a safety net. Trade Plan: - Suggested Entry: $44.60 - Stop Loss: $42.50 (approximately 4.7% risk) - Take Profit Targets: 1. $47.00 (7.6% gain) 2. $49.00 (10.5% gain) 3. $52.00 (16.5% gain) With a potential ROI of over 17% on the third target, this trade offers a favorable risk-reward ratio. Monitor closely for price action near MAs. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:09 AM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $44.74, with an RSI of 35.7 indicating it is in oversold territory. This suggests potential for upward movement as buyers may step in. The stock is positioned between its 60D high of $50.27 and low of $30.81, providing a clear range for potential price action. Directional Bias: The recent price is below both the 30-day moving average (MA30) of $45.9 and the 50-day moving average (MA50) of $44.32, indicating bearish sentiment. However, the low RSI suggests a reversal could be imminent. Trade Plan: - Suggested Entry: $44.74 - Stop Loss: $42.00 (approx. 6% risk) - Take Profit Targets: 1. Target 1: $47.00 (5.1% gain) 2. Target 2: $49.00 (9.9% gain) 3. Target 3: $52.50 (17.5% gain) This plan offers a potential ROI of over 17% on the third target while maintaining a reasonable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:57 PM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $46.5, within a defined range of the 60D high of $50.27 and low of $30.81. The stock shows a neutral RSI of 44.33, indicating it is not overbought or oversold. The MA30 at $45.9 is slightly above the current price, while the MA50 at $44.13 suggests potential support. Directional Bias: The price is positioned between the MA30 and MA50, indicating a possible bullish reversal if it breaks above the MA30. The ATR of 2.22 suggests moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $46.5 - Stop Loss: $43.5 (approximately 6.4% below entry) - Take Profit Targets: 1. TP1: $48.5 (4.3% gain) 2. TP2: $50.0 (7.9% gain) 3. TP3: $54.5 (17.3% gain) This plan aims for a minimum of 17% ROI on TP3, leveraging the potential upward movement within the current price range. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:57 AM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $46.07, showing a neutral RSI of 51.35, indicating neither overbought nor oversold conditions. The stock is above its 30-day moving average (MA30) of $45.6 and significantly above its 50-day moving average (MA50) of $43.59, suggesting a bullish short-term trend. Directional Bias: The recent price action is supported by the 60-day high of $50.27, indicating potential upward momentum. The stock remains well above the 60-day low of $30.81, reinforcing a bullish outlook. Trade Plan: - Suggested Entry: $46.07 - Stop Loss: $43.50 (approximately 5.6% below entry) - Take Profit Targets: 1. Target 1: $48.00 (4.2% gain) 2. Target 2: $49.50 (5.2% gain) 3. Target 3: $54.00 (17.3% gain) With a solid risk-reward ratio, this trade plan aims for a minimum of 17% ROI on the third target. Execute with caution and monitor market conditions. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Latest News on PCVX
Vaxcyte: Financial Durability And The Case For Disruption

Dec 16, 2025, 9:26 AM EST - 10 days ago

Vaxcyte: Financial Durability And The Case For Disruption


Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

May 1, 2025, 8:00 AM EDT - 8 months ago

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors


Vaccine stocks fall following FDA resignation

Mar 31, 2025, 6:21 PM EDT - 9 months ago

Vaccine stocks fall following FDA resignation

BNTX MRNA NVAX PFE PTCT XBI


Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 3:26 AM EST - 10 months ago

Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript


Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 4:05 PM EST - 11 months ago

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference


Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

Jan 30, 2025, 11:51 AM EST - 11 months ago

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm


Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy

Jan 15, 2025, 7:15 AM EST - 1 year ago

Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy

PFE


Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Sep 4, 2024, 11:58 PM EDT - 1 year ago

Vaxcyte Announces Pricing of $1.3 Billion Public Offering


Vaxcyte Appoints John Furey to Board of Directors

Jul 2, 2024, 8:30 AM EDT - 1 year ago

Vaxcyte Appoints John Furey to Board of Directors


Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 12:32 AM EST - 1 year ago

Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript


Vaxcyte Announces Pricing of $750 Million Public Offering

Jan 30, 2024, 11:37 PM EST - 2 years ago

Vaxcyte Announces Pricing of $750 Million Public Offering


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:57 PM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $47.65, showing a stable position above the 30-day moving average (MA30) of $46.66 and the 50-day moving average (MA50) of $45.21. The RSI at 56.89 indicates bullish momentum without being overbought, suggesting potential for upward movement. Directional Bias: The recent price action is positive, as the stock is closer to the 60-day high of $50.27 than the low of $36.15. This indicates a bullish sentiment in the market. Trade Plan: - Suggested Entry: $47.70 (slightly above last close) - Stop Loss: $45.50 (below MA50 for safety) - Take Profit Targets: 1. $49.00 (4% gain) 2. $50.00 (5.5% gain) 3. $55.75 (17% gain) This plan leverages the current bullish trend while maintaining a reasonable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
TheNewNormalN
TheNewNormalN Dec. 25 at 11:36 AM
$PCVX A transition phase is underway where operating consistency matters more than rapid expansion. Operating leverage needs to emerge without sacrificing balance‑sheet resilience. Sharper prioritization may be required to avoid execution dilution. The market will respond to evidence, not speculation.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:54 PM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $43.71, showing a significant decline from its 60-day high of $50.27. The RSI at 31.81 indicates that the stock is oversold, suggesting a potential reversal. The price is also below both the 30-day MA (46.06) and the 50-day MA (44.86), indicating bearish momentum, but the oversold RSI presents a buying opportunity. Directional Bias: Given the oversold condition and proximity to the 60-day low of $31.89, we anticipate a bullish reversal. Trade Plan: - Suggested Entry: $43.71 - Stop Loss: $41.57 (approximately 5% below entry) - Take Profit Targets: - TP1: $46.00 (5.25% gain) - TP2: $48.00 (9.76% gain) - TP3: $51.00 (16.54% gain) This plan offers a potential ROI of over 17% on TP3 while maintaining a manageable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:39 AM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $43.67, significantly below the 30-day moving average (MA30) of $45.89 and the 50-day moving average (MA50) of $44.77, indicating bearish momentum. The RSI at 28.93 suggests the stock is oversold, presenting a potential reversal opportunity. Directional Bias: Given the oversold RSI and proximity to the 60-day low of $31.89, there is a bullish bias for a potential recovery towards the 60-day high of $50.27. Trade Plan: - Suggested Entry: $43.67 (last close) - Stop Loss: $41.57 (below recent support, approximately 5% risk) - Take Profit Targets: 1. $46.00 (10% gain) 2. $48.00 (10% gain) 3. $51.00 (17% gain) This plan allows for a risk-reward ratio that aligns with a potential recovery, leveraging the oversold condition and recent price action. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:12 AM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $44.5, showing potential for upward movement. The RSI at 40.48 indicates that the stock is approaching oversold territory, suggesting a possible rebound. The proximity to the 60D Low of $30.89 provides a favorable risk-reward setup. Directional Bias: The stock is below both the MA30 (45.89) and MA50 (44.69), indicating bearish pressure. However, the RSI suggests a potential reversal, and the recent price action is near the lower end of its 60-day range. Trade Plan: - Suggested Entry: $44.5 - Stop Loss: $42.5 (1.5 ATR below entry) - Take Profit Targets: - TP1: $46.5 (4.5% gain) - TP2: $48.0 (7.5% gain) - TP3: $52.0 (17% gain) This trade plan offers a clear path for profit while managing risk effectively. Monitor the stock closely for any changes in momentum. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
infiniteM
infiniteM Dec. 13 at 8:21 AM
$PCVX tokd you....
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:06 AM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $44.57, showing a neutral RSI of 41.0, indicating potential for upward movement as it is not overbought. The price is below the 30-day moving average (MA30) of $45.9 and slightly above the 50-day moving average (MA50) of $44.6, suggesting a possible reversal or consolidation phase. Directional Bias: Given the RSI and proximity to both MAs, there is a bullish bias. The recent 60-day high of $50.27 presents a target for upward momentum, while the 60-day low of $30.89 provides a safety net. Trade Plan: - Suggested Entry: $44.60 - Stop Loss: $42.50 (approximately 4.7% risk) - Take Profit Targets: 1. $47.00 (7.6% gain) 2. $49.00 (10.5% gain) 3. $52.00 (16.5% gain) With a potential ROI of over 17% on the third target, this trade offers a favorable risk-reward ratio. Monitor closely for price action near MAs. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:09 AM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $44.74, with an RSI of 35.7 indicating it is in oversold territory. This suggests potential for upward movement as buyers may step in. The stock is positioned between its 60D high of $50.27 and low of $30.81, providing a clear range for potential price action. Directional Bias: The recent price is below both the 30-day moving average (MA30) of $45.9 and the 50-day moving average (MA50) of $44.32, indicating bearish sentiment. However, the low RSI suggests a reversal could be imminent. Trade Plan: - Suggested Entry: $44.74 - Stop Loss: $42.00 (approx. 6% risk) - Take Profit Targets: 1. Target 1: $47.00 (5.1% gain) 2. Target 2: $49.00 (9.9% gain) 3. Target 3: $52.50 (17.5% gain) This plan offers a potential ROI of over 17% on the third target while maintaining a reasonable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:57 PM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $46.5, within a defined range of the 60D high of $50.27 and low of $30.81. The stock shows a neutral RSI of 44.33, indicating it is not overbought or oversold. The MA30 at $45.9 is slightly above the current price, while the MA50 at $44.13 suggests potential support. Directional Bias: The price is positioned between the MA30 and MA50, indicating a possible bullish reversal if it breaks above the MA30. The ATR of 2.22 suggests moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $46.5 - Stop Loss: $43.5 (approximately 6.4% below entry) - Take Profit Targets: 1. TP1: $48.5 (4.3% gain) 2. TP2: $50.0 (7.9% gain) 3. TP3: $54.5 (17.3% gain) This plan aims for a minimum of 17% ROI on TP3, leveraging the potential upward movement within the current price range. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:57 AM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $46.07, showing a neutral RSI of 51.35, indicating neither overbought nor oversold conditions. The stock is above its 30-day moving average (MA30) of $45.6 and significantly above its 50-day moving average (MA50) of $43.59, suggesting a bullish short-term trend. Directional Bias: The recent price action is supported by the 60-day high of $50.27, indicating potential upward momentum. The stock remains well above the 60-day low of $30.81, reinforcing a bullish outlook. Trade Plan: - Suggested Entry: $46.07 - Stop Loss: $43.50 (approximately 5.6% below entry) - Take Profit Targets: 1. Target 1: $48.00 (4.2% gain) 2. Target 2: $49.50 (5.2% gain) 3. Target 3: $54.00 (17.3% gain) With a solid risk-reward ratio, this trade plan aims for a minimum of 17% ROI on the third target. Execute with caution and monitor market conditions. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:31 PM
Actionable Trade Alert for $PCVX: Market Context: $PCVX is currently trading at $46.07, showing a neutral RSI of 51.35, indicating neither overbought nor oversold conditions. The stock is above its 30-day moving average (MA30) of $45.6 and significantly above its 50-day moving average (MA50) of $43.59, suggesting a bullish short-term trend. Directional Bias: The recent price action is supported by the 60-day high of $50.27, indicating potential upward momentum. The stock remains well above the 60-day low of $30.81, reinforcing a bullish outlook. Trade Plan: - Suggested Entry: $46.07 - Stop Loss: $43.50 (approximately 5.6% below entry) - Take Profit Targets: 1. Target 1: $48.00 (4.2% gain) 2. Target 2: $49.50 (5.2% gain) 3. Target 3: $54.00 (17.3% gain) With a solid risk-reward ratio, this trade plan aims for a minimum of 17% ROI on the third target. Execute with caution and monitor market conditions. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 5 at 6:59 PM
$PCVX Current Stock Price: $45.82 Contracts to trade: $45 PCVX Dec 19 2025 Call Entry: $0.40 Exit: $0.77 ROI: 93% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Tokenist
Tokenist Dec. 1 at 4:34 PM
🔥 $MRNA gets hit as FDA signals tougher vaccine rules Moderna is sliding after an FDA memo revealed plans for stricter vaccine-approval requirements. $MRNA dropped over 4%, with traders worried this could delay key programs like its upcoming flu shot and its flu/COVID combo vaccine. Analysts are warning that the new safety demands could slow Moderna’s entire pipeline at the worst possible time. The stock is already down 40%+ YTD, and Q3 revenue slipped to $1.02B with a $200M loss. The sell-off isn’t isolated either — $BNTX, $NVAX, and $PCVX all took hits as the FDA shifts toward tighter oversight under HHS Secretary RFK Jr. With $MRNA now trading near $24 and heavy regulatory pressure building, the road ahead just got a lot tougher for Moderna bulls. 💉📉
1 · Reply
Stmkr
Stmkr Nov. 30 at 5:45 AM
$PCVX $XBI the full email as posted by AF https://x.com/adamfeuerstein/status/1994884960894029846?s=19
0 · Reply
justiceforb_85
justiceforb_85 Nov. 30 at 3:50 AM
$PCVX concerned about price action on Monday though feel a dip would be a buying opportunity as VAX-31 is likely best-in-class. Now issue will be over what the trial outcomes entail if not serologic testing.
0 · Reply
Stmkr
Stmkr Nov. 29 at 2:48 PM
$PCVX $XBI "“I remain open to vigorous discussions and debate,” Prasad wrote to his team, adding that staff who did not agree with the core principles of his new approach should submit their resignations."...
0 · Reply
Stmkr
Stmkr Nov. 29 at 2:47 PM
$PCVX $XBI This will be terrible for makers of pneumonia vaccines... "For instance, Prasad said that pneumonia vaccine makers must demonstrate that their products reduce pneumonia rather than just generate antibodies to fight infections." https://www.washingtonpost.com/health/2025/11/29/fda-vaccine-approval-child-covid-deaths/
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 23 at 3:47 PM
0 · Reply
justiceforb_85
justiceforb_85 Nov. 20 at 8:41 PM
$PCVX added. Think this will hopefully be in a better spot in 3-6 months. Likely best-in-class pneumococcal vaccine in the pipeline.
0 · Reply
StockConsultant
StockConsultant Nov. 16 at 11:33 PM
$PCVX Vaxcyte stock, nice top of range breakout, from Stocks to Watch at https://stockconsultant.com/?PCVX
0 · Reply
FonsieTrader
FonsieTrader Nov. 15 at 4:47 PM
$PCVX — STRONG WEEKLY TREND REVERSAL PCVX just printed one of the cleanest weekly momentum reversals on the biotech side. Price reclaimed all major trend levels, broke out of the multi-month base, and is now pushing with rising volume + tightening volatility — exactly what you want to see in early-stage reversals. MFI and OBV both confirm fresh accumulation, while ADX starts turning up from deep lows — classic setup for a multi-week continuation leg. As long as price holds above $45$46, bulls remain fully in control. Next key zones sit around $55$62, with room for a larger swing if momentum expands. This chart is transitioning from downtrend → accumulation → expansion. Textbook reversal structure.
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 10:31 AM
BTIG has updated their rating for Vaxcyte ( $PCVX ) to Buy with a price target of 85.
0 · Reply